Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca00b0fb3619702b1140e8038ae46d6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35ab6ae74ebc78ebc636cfd16d28cb72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d3ab71a987b95bb45e1a74fe157935b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03c01a64374df6d53b92e1aa712bf21c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
filingDate |
2019-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bfd0565e452e3b4e1d954e3b2b1f780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a52eaaf8b0c282ae8990951651d8288e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e10bf64a486bb9803514bc50f11df6b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fed2e66aab2982b970847bbb55a9be1a |
publicationDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020129455-A1 |
titleOfInvention |
Composition and method for treating neurological disease |
abstract |
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof. |
priorityDate |
2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |